IDH3A and central nervous system cancer: The WHO Classification of the Central Nervous System Tumors, 5th edition, published in 2021, describes the presence or absence of isocitrate dehydrogenase (IDH) mutation as one of the essential findings in the diagnosis of adult diffuse glioma [1–9].